<DOC>
	<DOCNO>NCT01810770</DOCNO>
	<brief_summary>To evaluate safety efficacy ( Overall survival [ OS ] ) multiple dose Ra-223 dichloride Asian population subject CRPC metastatic bone .</brief_summary>
	<brief_title>Radium-223 Dichloride Asian Population Study Treatment CRPC Patients With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Patients diagnose progressive bone predominant metastatic CastrationResistant Prostate Cancer ( CRPC ) /Hormone Refractory Prostate Cancer ( HRPC ) least 2 skeletal metastasis image lung , liver , and/or brain metastasis ( lymph node metastasis allow ) Known hormone refractory disease No intention use cytotoxic chemotherapy within next 6 month Either regular ( occasional ) analgesic medication use cancer relate bone pain treatment external bean radiation therapy ( EBRT ) bone pain within previous 12 week Age &gt; /= 18 year Race Asian Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 02 Life expectancy &gt; /= 6 month Adequate bone marrow , liver renal function assess Laboratory require protocol Treatment investigational drug within previous 4 week prior screen , plan treatment followup period Eligible docetaxel treatment , i.e . subject fit enough , willing locate treatment docetaxel available Treatment cytotoxic chemotherapy within previous 4 week prior screen , failure recover adverse event due cytotoxic chemotherapy administer 4 week prior screen ( however ongoing neuropathy permit ) Prior hemibody external radiotherapy exclude . Subjects receive type prior external radiotherapy allow provide bone marrow function assess meet protocol requirement hemoglobin , absolute neutrophil count platelet . Received systemic therapy radionuclides ( e.g. , strontium89 , samarium153 , rhenium186 , rhenium188 , radium223 dichloride ) treatment bony metastasis Blood transfusion erythropoetin stimulate agent within previous 4 week prior screen Other malignancy treat within last 3 year ( except nonmelanoma skin cancer lowgrade superficial bladder cancer ) Visceral metastasis assess abdominal/pelvic compute tomography ( CT ) image modality Presence brain metastasis Lymphadenopathy exceed 3 cm shortaxis diameter Any size pelvic lymphadenopathy think contributor concurrent hydronephrosis Imminent establish spinal cord compression base clinical finding and/or magnetic resonance imaging ( MRI ) . Subjects history spinal cord compression completely recover . Received local practice implant therapy contain lodine125 Palladium103 primary lesion prostate cancer within 6 month prior screen . Any serious illness medical condition</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Radium-223 Dichloride</keyword>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Bone Metastasis</keyword>
</DOC>